Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Phase II study of TAS-OX (TAS-102 and oxaliplatin) plus bevacizumab for late-line colorectal cancer.
Authors
Howard S. Hochster
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ;
Howard S. Hochster , Hao Liu , Lyudmyla Derby Berim , Kristen Renee Spencer , Pat Gulhati , Manda DiRubbo , Seth D. Cohen , Patrick Lee , Stuart P. Leitner , Delia Radovich , Christian Misdary , Christian Perez , Sutirtha Datta , Andrea Gonzalez , Tracie Saunders , Patrick M Boland
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04294264
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 144)
DOI
10.1200/JCO.2023.41.4_suppl.144
Abstract #
144
Poster Bd #
H3
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase 1/2 evaluation of revumenib in patients with advanced colorectal cancer and other solid tumors.
First Author: Aparna Raj Parikh
Poster
2024 ASCO Gastrointestinal Cancers Symposium
First report of the randomized phase III study of bi-weekly trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) vs. FTD/TPI monotherapy for chemorefractory metastatic colorectal cancer (mCRC): JCOG2014 (ROBiTS).
First Author: Hironaga Satake
Poster
2023 ASCO Annual Meeting
Phase II study of biweekly TAS-102, irinotecan and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO).
First Author: Patrick M Boland
Poster
2023 ASCO Annual Meeting
OniLon: Phase II trial of trifluridine/tipiracil (TAS-102) and nanoliposomal irinotecan (nal-IRI) in advanced colorectal cancer.
First Author: Olatunji B. Alese